TuHURA Biosciences, Inc.
This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult participant (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine participants will receive IFx-Hu2.0 as a visceral/nodal lesion injection followed by pembrolizumab.
Inclusion Criteria: 1. At least 18 years of age. 2. Life expectancy equal to or greater than six months. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status \< 2. 4. Has measurable disease as defined by RECIST v1.1 5. Must be recurrent and/or unresectable Stage III or Stage IV American Joint Committee on Cancer (AJCC) (8th edition) and have histologically confirmed advanced or metastatic Merkel cell carcinoma a. Must have at least one deep-seated visceral/nodal greater than 3 mm in its longest diameter 6. Subject should be CPI naïve i.e., no prior therapy with CPI including bu…
Therapeutic Classification: • Innate immune agonist Route of Administration: • Intralesional
Therapeutic Classification: • Immunotherapy (Immune checkpointinhibitor) Route of administration: • Intravenous (IV) infusion
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.